EPISODE · May 20, 2026 · 1 MIN
Penpulimab Regimens May Improve Outcomes in Resectable NSCLC
from TheBrief.Health · host TheBrief.Health
Emerging combination therapy using penpulimab, anlotinib, and chemotherapy shows promise for improving pathological response and survival outcomes in resectable non-small cell lung cancer.
What this episode covers
Emerging combination therapy using penpulimab, anlotinib, and chemotherapy shows promise for improving pathological response and survival outcomes in resectable non-small cell lung cancer.
NOW PLAYING
Penpulimab Regimens May Improve Outcomes in Resectable NSCLC
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m